(Q35800774)

10 August 2017

13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme (English)

1 reference

10 August 2017

1 reference

Siew-Ju See

1

1 reference

10 August 2017

Victor A Levin

2

1 reference

10 August 2017

W-K Alfred Yung

3

1 reference

10 August 2017

Kenneth R Hess

4

1 reference

10 August 2017

Morris D Groves

5

1 reference

10 August 2017

1 July 2004

1 reference

10 August 2017

1 reference

10 August 2017

6

1 reference

10 August 2017

3

1 reference

10 August 2017

253-258

1 reference

Retinoic acid receptors inhibit AP1 activation by regulating extracellular signal-regulated kinase and CBP recruitment to an AP1-responsive promoter

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871997

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871997

Agonists of the retinoic acid- and retinoid X-receptors inhibit hepatocyte growth factor secretion and expression in U87 human astrocytoma cells.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871997

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871997

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871997

Effects of retinoic acid and tumor necrosis factor alpha on GL-15 glioblastoma cells

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871997

Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871997

Retinoic acid and 1,25-dihydroxyvitamin D3 inhibit tenascin-C expression in rat glioma C6 cells

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871997

Phase II study of paclitaxel in patients with recurrent malignant glioma.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871997

All-trans-retinoic acid in acute promyelocytic leukemia and its potential in other hematologic malignancies.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871997

A phase II study of intravenous carboplatin for the treatment of recurrent gliomas.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871997

Modulation of growth and epidermal growth factor receptor activity by retinoic acid in human glioma cells.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871997

Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871997

Intravenous carboplatin for recurrent malignant glioma: a phase II study

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871997

Regulation by retinoic acid of ICAM-1 expression on human tumor cell lines.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871997

Irinotecan therapy in adults with recurrent or progressive malignant glioma.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871997

Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871997

Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871997

Retinoids inhibit the oxidative modification of protein kinase C induced by oxidant tumor promoters

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871997

Treatment of advanced squamous cell carcinoma of the skin with isotretinoin

25 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15279718

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Treatment of advanced squamous cell carcinoma of the head and neck with isotretinoin: a phase II randomized trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15279718

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1215/S1152851703000607

1 reference

10 August 2017

1 reference

10 August 2017

1 reference